Zydus Lifesciences’ shares fell 6% to Rs 1,109 after acquiring a 50% stake in Sterling Biotech for Rs 550 crore. Analysts maintain neutral ratings with target prices of Rs 1,020 and Rs 1,210.
Sebi warns of no regulatory recourse for investors trading in unlisted securities
Sebi has cautioned investors against trading unlisted securities through unauthorized websites and electronic platforms. The regulator said such platforms operate outside its oversight, leaving investors